Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-6 of 6 for your search:
Drug:
ramucirumab
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0606
, TRI0-CIRG-012, TRI0-012, NCT00703326
2.
Study Using IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer, Following Disease Progression on Docetaxel-Based Chemotherapy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP18-0601
, NCT00683475
3.
Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0711
, NCT00721162
4.
A Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-Line Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0708
, NCT00735696
5.
Study of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin Chemotherapies in Patients With Colorectal Cancer
Phase:
Phase II
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0709
, NCT00862784
6.
Phase II Study of Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Patients With Recurrent Glioblastoma Multiforme
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0901
, ABTC 0901
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute